Selected research
Market Structure
Global ADC Drug CDMO Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global ADC Drug CDMO Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for ADC Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for ADC Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for ADC Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for ADC Drug CDMO Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of ADC Drug CDMO Service include Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Axplora and Aji Bio-Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global ADC Drug CDMO Service market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of ADC Drug CDMO Service and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents ADC Drug CDMO Service revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the ADC Drug CDMO Service market size, projected growth trends, production technologies, key applications, and end-use industries.
ADC Drug CDMO Service Segment by Company
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech
ADC Drug CDMO Service Segment by Type
Cleavable Linkers
Non-cleavable Linkers
ADC Drug CDMO Service Segment by Application
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies
ADC Drug CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ADC Drug CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of ADC Drug CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ADC Drug CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of ADC Drug CDMO Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global ADC Drug CDMO Service industry.
Chapter 3: Detailed analysis of ADC Drug CDMO Service companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, ADC Drug CDMO Servicerevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Cleavable Linkers
- Non-cleavable Linkers
Applications
- Small and Medium-sized Pharmaceutical Companies
- Large Pharmaceutical Companies
Companies covered
- Lonza Group
- Merck KGaA
- WuXi XDC
- Abbvie
- Piramal Pharma Solutions
- Catalent
- Sterling Pharma Solutions
- Axplora
- Aji Bio-Pharma
- BSP Pharmaceuticals
- Cerbios-Pharma
- Goodwin Biotechnology
- TOT Biopharm
- Huadong Medicine
- Innovent Biologics
- Shanghai Henlius Biotech
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global ADC Drug CDMO Service Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Cleavable Linkers
- 1.2.3 Non-cleavable Linkers
- 1.3 Market Analysis by Application
- 1.3.1 Global ADC Drug CDMO Service Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Small and Medium-sized Pharmaceutical Companies
- 1.3.3 Large Pharmaceutical Companies
- 1.4 Global Market Growth Prospects
- 1.5 Global ADC Drug CDMO Service Growth Trends by Region
- 1.5.1 Global ADC Drug CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 ADC Drug CDMO Service Market Size by Region (2021-2026)
- 1.5.3 ADC Drug CDMO Service Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global ADC Drug CDMO Service Market Dynamics
- 2.1 ADC Drug CDMO Service Industry Trends
- 2.2 ADC Drug CDMO Service Industry Drivers
- 2.3 ADC Drug CDMO Service Industry Opportunities and Challenges
- 2.4 ADC Drug CDMO Service Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global ADC Drug CDMO Service Revenue by Company (2021-2026)
- 3.2 Global ADC Drug CDMO Service Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global ADC Drug CDMO Service Key Company Head office and Area Served
- 3.4 Global ADC Drug CDMO Service Company, Product Type & Application
- 3.5 Global ADC Drug CDMO Service Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global ADC Drug CDMO Service Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 ADC Drug CDMO Service Players Market Share by Revenue in 2025
- 3.6.3 2025 ADC Drug CDMO Service Tier 1, Tier 2, and Tier 3
4 ADC Drug CDMO Service Market by Type
- 4.1 Global ADC Drug CDMO Service Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global ADC Drug CDMO Service Market Size by Type (2021-2032)
- 4.3 Global ADC Drug CDMO Service Market Size Share by Type (2021-2032)
5 ADC Drug CDMO Service Market by Application
- 5.1 Global ADC Drug CDMO Service Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global ADC Drug CDMO Service Market Size by Application (2021-2032)
- 5.3 Global ADC Drug CDMO Service Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Lonza Group
- 6.1.1 Lonza Group Company Information
- 6.1.2 Lonza Group Business Overview
- 6.1.3 Lonza Group ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Lonza Group ADC Drug CDMO Service Product Portfolio
- 6.1.5 Lonza Group Recent Developments
- 6.2 Merck KGaA
- 6.2.1 Merck KGaA Company Information
- 6.2.2 Merck KGaA Business Overview
- 6.2.3 Merck KGaA ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Merck KGaA ADC Drug CDMO Service Product Portfolio
- 6.2.5 Merck KGaA Recent Developments
- 6.3 WuXi XDC
- 6.3.1 WuXi XDC Company Information
- 6.3.2 WuXi XDC Business Overview
- 6.3.3 WuXi XDC ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 WuXi XDC ADC Drug CDMO Service Product Portfolio
- 6.3.5 WuXi XDC Recent Developments
- 6.4 Abbvie
- 6.4.1 Abbvie Company Information
- 6.4.2 Abbvie Business Overview
- 6.4.3 Abbvie ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Abbvie ADC Drug CDMO Service Product Portfolio
- 6.4.5 Abbvie Recent Developments
- 6.5 Piramal Pharma Solutions
- 6.5.1 Piramal Pharma Solutions Company Information
- 6.5.2 Piramal Pharma Solutions Business Overview
- 6.5.3 Piramal Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Piramal Pharma Solutions ADC Drug CDMO Service Product Portfolio
- 6.5.5 Piramal Pharma Solutions Recent Developments
- 6.6 Catalent
- 6.6.1 Catalent Company Information
- 6.6.2 Catalent Business Overview
- 6.6.3 Catalent ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Catalent ADC Drug CDMO Service Product Portfolio
- 6.6.5 Catalent Recent Developments
- 6.7 Sterling Pharma Solutions
- 6.7.1 Sterling Pharma Solutions Company Information
- 6.7.2 Sterling Pharma Solutions Business Overview
- 6.7.3 Sterling Pharma Solutions ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Sterling Pharma Solutions ADC Drug CDMO Service Product Portfolio
- 6.7.5 Sterling Pharma Solutions Recent Developments
- 6.8 Axplora
- 6.8.1 Axplora Company Information
- 6.8.2 Axplora Business Overview
- 6.8.3 Axplora ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Axplora ADC Drug CDMO Service Product Portfolio
- 6.8.5 Axplora Recent Developments
- 6.9 Aji Bio-Pharma
- 6.9.1 Aji Bio-Pharma Company Information
- 6.9.2 Aji Bio-Pharma Business Overview
- 6.9.3 Aji Bio-Pharma ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Aji Bio-Pharma ADC Drug CDMO Service Product Portfolio
- 6.9.5 Aji Bio-Pharma Recent Developments
- 6.10 BSP Pharmaceuticals
- 6.10.1 BSP Pharmaceuticals Company Information
- 6.10.2 BSP Pharmaceuticals Business Overview
- 6.10.3 BSP Pharmaceuticals ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 BSP Pharmaceuticals ADC Drug CDMO Service Product Portfolio
- 6.10.5 BSP Pharmaceuticals Recent Developments
- 6.11 Cerbios-Pharma
- 6.11.1 Cerbios-Pharma Company Information
- 6.11.2 Cerbios-Pharma Business Overview
- 6.11.3 Cerbios-Pharma ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Cerbios-Pharma ADC Drug CDMO Service Product Portfolio
- 6.11.5 Cerbios-Pharma Recent Developments
- 6.12 Goodwin Biotechnology
- 6.12.1 Goodwin Biotechnology Company Information
- 6.12.2 Goodwin Biotechnology Business Overview
- 6.12.3 Goodwin Biotechnology ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Goodwin Biotechnology ADC Drug CDMO Service Product Portfolio
- 6.12.5 Goodwin Biotechnology Recent Developments
- 6.13 TOT Biopharm
- 6.13.1 TOT Biopharm Company Information
- 6.13.2 TOT Biopharm Business Overview
- 6.13.3 TOT Biopharm ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 TOT Biopharm ADC Drug CDMO Service Product Portfolio
- 6.13.5 TOT Biopharm Recent Developments
- 6.14 Huadong Medicine
- 6.14.1 Huadong Medicine Company Information
- 6.14.2 Huadong Medicine Business Overview
- 6.14.3 Huadong Medicine ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Huadong Medicine ADC Drug CDMO Service Product Portfolio
- 6.14.5 Huadong Medicine Recent Developments
- 6.15 Innovent Biologics
- 6.15.1 Innovent Biologics Company Information
- 6.15.2 Innovent Biologics Business Overview
- 6.15.3 Innovent Biologics ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Innovent Biologics ADC Drug CDMO Service Product Portfolio
- 6.15.5 Innovent Biologics Recent Developments
- 6.16 Shanghai Henlius Biotech
- 6.16.1 Shanghai Henlius Biotech Company Information
- 6.16.2 Shanghai Henlius Biotech Business Overview
- 6.16.3 Shanghai Henlius Biotech ADC Drug CDMO Service Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Shanghai Henlius Biotech ADC Drug CDMO Service Product Portfolio
- 6.16.5 Shanghai Henlius Biotech Recent Developments
7 North America
- 7.1 North America ADC Drug CDMO Service Market Size (2021-2032)
- 7.2 North America ADC Drug CDMO Service Market Size by Type
- 7.2.1 North America ADC Drug CDMO Service Market Size by Type (2021-2026)
- 7.2.2 North America ADC Drug CDMO Service Market Size by Type (2027-2032)
- 7.2.3 North America ADC Drug CDMO Service Market Share by Type (2021-2032)
- 7.3 North America ADC Drug CDMO Service Market Size by Application
- 7.3.1 North America ADC Drug CDMO Service Market Size by Application (2021-2026)
- 7.3.2 North America ADC Drug CDMO Service Market Size by Application (2027-2032)
- 7.3.3 North America ADC Drug CDMO Service Market Share by Application (2021-2032)
- 7.4 North America ADC Drug CDMO Service Market Size by Country
- 7.4.1 North America ADC Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America ADC Drug CDMO Service Market Size by Country (2021-2026)
- 7.4.3 North America ADC Drug CDMO Service Market Size by Country (2027-2032)
- 7.4.4 North America ADC Drug CDMO Service Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe ADC Drug CDMO Service Market Size (2021-2032)
- 8.2 Europe ADC Drug CDMO Service Market Size by Type
- 8.2.1 Europe ADC Drug CDMO Service Market Size by Type (2021-2026)
- 8.2.2 Europe ADC Drug CDMO Service Market Size by Type (2027-2032)
- 8.2.3 Europe ADC Drug CDMO Service Market Share by Type (2021-2032)
- 8.3 Europe ADC Drug CDMO Service Market Size by Application
- 8.3.1 Europe ADC Drug CDMO Service Market Size by Application (2021-2026)
- 8.3.2 Europe ADC Drug CDMO Service Market Size by Application (2027-2032)
- 8.3.3 Europe ADC Drug CDMO Service Market Share by Application (2021-2032)
- 8.4 Europe ADC Drug CDMO Service Market Size by Country
- 8.4.1 Europe ADC Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe ADC Drug CDMO Service Market Size by Country (2021-2026)
- 8.4.3 Europe ADC Drug CDMO Service Market Size by Country (2027-2032)
- 8.4.4 Europe ADC Drug CDMO Service Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China ADC Drug CDMO Service Market Size (2021-2032)
- 9.2 China ADC Drug CDMO Service Market Size by Type
- 9.2.1 China ADC Drug CDMO Service Market Size by Type (2021-2026)
- 9.2.2 China ADC Drug CDMO Service Market Size by Type (2027-2032)
- 9.2.3 China ADC Drug CDMO Service Market Share by Type (2021-2032)
- 9.3 China ADC Drug CDMO Service Market Size by Application
- 9.3.1 China ADC Drug CDMO Service Market Size by Application (2021-2026)
- 9.3.2 China ADC Drug CDMO Service Market Size by Application (2027-2032)
- 9.3.3 China ADC Drug CDMO Service Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia ADC Drug CDMO Service Market Size (2021-2032)
- 10.2 Asia ADC Drug CDMO Service Market Size by Type
- 10.2.1 Asia ADC Drug CDMO Service Market Size by Type (2021-2026)
- 10.2.2 Asia ADC Drug CDMO Service Market Size by Type (2027-2032)
- 10.2.3 Asia ADC Drug CDMO Service Market Share by Type (2021-2032)
- 10.3 Asia ADC Drug CDMO Service Market Size by Application
- 10.3.1 Asia ADC Drug CDMO Service Market Size by Application (2021-2026)
- 10.3.2 Asia ADC Drug CDMO Service Market Size by Application (2027-2032)
- 10.3.3 Asia ADC Drug CDMO Service Market Share by Application (2021-2032)
- 10.4 Asia ADC Drug CDMO Service Market Size by Country
- 10.4.1 Asia ADC Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia ADC Drug CDMO Service Market Size by Country (2021-2026)
- 10.4.3 Asia ADC Drug CDMO Service Market Size by Country (2027-2032)
- 10.4.4 Asia ADC Drug CDMO Service Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa ADC Drug CDMO Service Market Size (2021-2032)
- 11.2 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Type
- 11.2.1 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa ADC Drug CDMO Service Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Application
- 11.3.1 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa ADC Drug CDMO Service Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Country
- 11.4.1 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa ADC Drug CDMO Service Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa ADC Drug CDMO Service Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst